New Phase I dose-expansion findings in relapsed or refractory small-cell lung cancer (SCLC) highlight how biomarker analysis can be used to track treatment efficacy in the AZD2811 program. The work—led by Johnson, Fabbri, Ciardullo and colleagues—focuses on the utility of biomarker readouts alongside clinical activity. AZD2811 is described as a novel therapeutic agent, and the biomarker component aims to connect molecular or clinical surrogate markers to changes in tumor activity during dose escalation and expansion. For SCLC, a disease where patient stratification and response prediction remain challenging, integrating biomarker-driven monitoring can improve translational relevance and potentially inform later trial design. While the report centers on early-phase data, it underscores a practical issue for biotech development: using biomarker signals not just for discovery, but as operational decision tools during early clinical evaluation.